Shares in California’s Gilead Sciences (Nasdaq: GILD) jumped in pre-market trading on Wednesday, as the firm announced a deal with privately-held biotech Precision BioSciences to develop therapies for the hepatitis B virus (HBV).
Gilead, which has recently faced mounting patent challenges over its HCV therapy Sovaldi (sofosbuvir), also announced positive results from a trial of its investigational JAK1 inhibitor filgotinib this week.
Under the terms of the collaboration, Precision will take the lead on developing investigational nucleases, and Gilead, which will fully fund the R&D, will take on clinical development and commercialization of potential therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze